SlideShare ist ein Scribd-Unternehmen logo
1 von 15
Business Plan Presentation
                    MEDICA 2010

MEDEVIEN SA     Konstantine Haralampopoulos   November 2010
Market Research for..

 Healthcare Products
  – H.Pylori
  – PSA
Helicobacter pylori
General Information: H.pylori causes conditions such as gastritis and
   ulcers in human beings. There is no immunisation for this type of bacterial
   infection and infection occurs as well in adults as in childs; however by
   suitable medication with antibiotics the bacterium can be killed. An
   infection with H.pylori also increases the chances of getting stomach
   cancer considerably
National Infection rate: 50% of healthy adults affected – one in
  two people. The majority undiagnosed
Potential Patients in Greece: 3.500.000 in Total Population
Current Diagnostic pathway:
 Laboratory examinations only available
o biopsy via gastroscopy
o breath test
o blood and fecal examination for Antibody tracing (rarely)
Current Diagnostic pathway

 Laboratory examinations only available
  o biopsy via gastroscopy
  o breath test
  o blood and fecal examination for Antibody tracing (rarely)
     o Blood testing cost up to 30€ per examination in private labs
The Self-Diagnostic device

• Stomach Ulcer Prevention
  test
   – the innovative self-testing
     solution
   – Simple, quick and painless
   – A new essential addition into
     the current diagnostic
     pathway
   – Accuracy rates comparable to
     all laboratory examination
     approaches
Stomach Ulcer self test

              Positives                         Negatives
•   First self-testing product in   •   Previous infection with
    the Greek market                    H.pylori can give a faulty
•   High Accuracy                       positive result
•   Easy to use                     •   Low awareness on H.pylori
•                                       bacteria
    High market potential
                                    •   Currently Immature market
•   Lack of direct competition
                                        in regards to self diagnosis
                                    •   Possible conflict with
                                        Private Laboratories
H. Pylori - Target Audience

 Public 30+ years old, all socio-economic classes,
  throughout Greece.
 Selling/Purchasing Points  Pharmacies
 Doctors  Pathologists, General Practitioners,
  Gastroenterologists
Strategic Plan

    Objectives            Strategies                  Tactics
                                           Design leaflets
                                               -Stomach Ulcer information
                                               leaflets for public
 Grow the market    Create Awareness          - Product leaflets for selling
                                               points and HP
 Establish the                            Promote product’s accuracy
                     Sales & Promotional       data and unique technical
  product               Activities             specifications in HPs
                                           Product’s introduction &
                                               detailing in Pharmacies and
 Gain Medical
                     Activate Consumer         targeted doctors
  Community’s           dynamics           Media-advertising campaign
  referrals                                Publicity in Professional
                                               magazines
                                           Exhibit in Medical Congress
Prostate Cancer

Infection rate: It is the most frequent malignancy for men above 45 years old. In
   Europe 7% of the total male population will develop the disease.
Potential Market in Greece: 2.500.000 in Total Male Population
Current Diagnostic pathway:
o Clinical examination & DRE
o PSA (Cost per examination 80€-102€ in Private labs)
         o Regular level below 4 ng/mL
         o Suspicious level 4-10 ng/mL
         o Dangerous level above 10 ng/mL
o Sonografy
o Biopsy
The Self-Diagnostic device

• PSA self-test
   –   the new self-testing solution
   –   Simple, quick and reliable
   –   Qualitative results
   –   1st step for PSA identification
PSA self-test

              Positives                         Negatives
•   First self-testing product in   •   Immature market in regards to
    the Greek market                    self diagnosis
                                    •   Not a complete examination with
•   High Accuracy                       specific quantitative results
•   Easy to use                     •   A further PSA lab examination is
•   Time saving                         required in case of a positive
                                        result
•   Lack of direct competition      •   Its reliability might be
                                        questioned
PSA - Target Audience

 Male Public 45+ years old, all socio-economic classes,
  throughout Greece.
 Selling/Purchasing Points  Pharmacies
 Doctors  Urologists, General Practitioners.
Strategic Plan

    Objectives                Strategies                  Tactics


                                               Design leaflets
 Penetrate the          Sales & Promotional       - Product leaflets for selling
  market                    Activities             points and HPs
                                               Promote product’s value &
                                                   convenience
 Establish the self
                         Activate Consumer     Product’s introduction &
  diagnostic solution       dynamics               detailing in Pharmacies and
                                                   targeted doctors
 Gain Medical                                 Publicity in Professional
                                                   magazines
  Community’s
                                               Dynamic Media campaign
  referrals
                                               Exhibit in the National
                                                   Urological congres
Healthcare products
                  Rolling forecast in # of eaches
       Month        Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov   Dec         YE
Year
       Type         Fcast   Fcast   Fcast   Fcast   Fcast   Fcast   Fcast   Fcast   Fcast   Fcast   Fcast Fcast
                                                                                                                  Total Fcast



       PSA          1000 1.000 1.500 2.000 3.000 3.000 2.000 1.000 2.500 3.500 3.500 2.500                         26.500
2011


       H.pylori                             500     750     1.000 1.000     500     1.000 1.500 2.000 1.500         9.750


       PSA          3.000 3.500 4.000 4.000 5.000 5.000 3.000 2.000 3.000 4.500 5.000 4.000                        46.000
2012


       H.pylori     2.000 2.000 3.000 3.000 3.500 3.500 3.000 2.000 3.000 3.500 4.000 3.000                        35.500


                  Depending on our Strategic Planning impact, forecast can
                            be revised upwards within Q2 2010
Thank you!

Weitere ähnliche Inhalte

Ähnlich wie Medevien Presentation at MEDICA 2010

(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
Pinky Fadullon
 
quest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCCquest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCC
finance34
 
quest diagnostics 111208_CSHCC
quest diagnostics 111208_CSHCCquest diagnostics 111208_CSHCC
quest diagnostics 111208_CSHCC
finance34
 
10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp
Piyush Patel
 
quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08
finance34
 
quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08
finance34
 

Ähnlich wie Medevien Presentation at MEDICA 2010 (20)

(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
 
quest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCCquest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCC
 
quest diagnostics 111208_CSHCC
quest diagnostics 111208_CSHCCquest diagnostics 111208_CSHCC
quest diagnostics 111208_CSHCC
 
International marketing Marketing Decisions on marketing MIX
International marketing Marketing Decisions on marketing MIXInternational marketing Marketing Decisions on marketing MIX
International marketing Marketing Decisions on marketing MIX
 
G7 Marketing plan and Commercialization
G7 Marketing plan and CommercializationG7 Marketing plan and Commercialization
G7 Marketing plan and Commercialization
 
10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp
 
Neolite Business Credential
Neolite Business CredentialNeolite Business Credential
Neolite Business Credential
 
quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08
 
quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08
 
mHealth Israel_Future of Integrated Individualized Healthcare_Roche Diagnostics
mHealth Israel_Future of Integrated Individualized Healthcare_Roche DiagnosticsmHealth Israel_Future of Integrated Individualized Healthcare_Roche Diagnostics
mHealth Israel_Future of Integrated Individualized Healthcare_Roche Diagnostics
 
5th Annual Recombinant Antibodies (2012) Pp
5th Annual Recombinant Antibodies (2012) Pp5th Annual Recombinant Antibodies (2012) Pp
5th Annual Recombinant Antibodies (2012) Pp
 
SpectraScience SCIE Executive Informational Overview PPT
SpectraScience SCIE Executive Informational Overview PPTSpectraScience SCIE Executive Informational Overview PPT
SpectraScience SCIE Executive Informational Overview PPT
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
 
Matching Customer's expectations for Innovative Future
Matching Customer's expectations for Innovative FutureMatching Customer's expectations for Innovative Future
Matching Customer's expectations for Innovative Future
 
Global Regenerative Academy IA2020.pdf
Global Regenerative Academy IA2020.pdfGlobal Regenerative Academy IA2020.pdf
Global Regenerative Academy IA2020.pdf
 
RPG Blizzard Case Study - RPGLS | Phase 1
RPG Blizzard Case Study - RPGLS | Phase 1RPG Blizzard Case Study - RPGLS | Phase 1
RPG Blizzard Case Study - RPGLS | Phase 1
 
Anteo Diagnostics Microcap Presentation October 2013
Anteo Diagnostics Microcap Presentation October 2013Anteo Diagnostics Microcap Presentation October 2013
Anteo Diagnostics Microcap Presentation October 2013
 
Diagnostics 2011-full-report
Diagnostics 2011-full-reportDiagnostics 2011-full-report
Diagnostics 2011-full-report
 
UKADC System Partners Meeting
UKADC System Partners MeetingUKADC System Partners Meeting
UKADC System Partners Meeting
 
The impact of innovation on the future of IVD
The impact of innovation on the future of IVDThe impact of innovation on the future of IVD
The impact of innovation on the future of IVD
 

Medevien Presentation at MEDICA 2010

  • 1. Business Plan Presentation MEDICA 2010 MEDEVIEN SA Konstantine Haralampopoulos November 2010
  • 2. Market Research for..  Healthcare Products – H.Pylori – PSA
  • 3. Helicobacter pylori General Information: H.pylori causes conditions such as gastritis and ulcers in human beings. There is no immunisation for this type of bacterial infection and infection occurs as well in adults as in childs; however by suitable medication with antibiotics the bacterium can be killed. An infection with H.pylori also increases the chances of getting stomach cancer considerably National Infection rate: 50% of healthy adults affected – one in two people. The majority undiagnosed Potential Patients in Greece: 3.500.000 in Total Population Current Diagnostic pathway:  Laboratory examinations only available o biopsy via gastroscopy o breath test o blood and fecal examination for Antibody tracing (rarely)
  • 4. Current Diagnostic pathway  Laboratory examinations only available o biopsy via gastroscopy o breath test o blood and fecal examination for Antibody tracing (rarely) o Blood testing cost up to 30€ per examination in private labs
  • 5. The Self-Diagnostic device • Stomach Ulcer Prevention test – the innovative self-testing solution – Simple, quick and painless – A new essential addition into the current diagnostic pathway – Accuracy rates comparable to all laboratory examination approaches
  • 6. Stomach Ulcer self test Positives Negatives • First self-testing product in • Previous infection with the Greek market H.pylori can give a faulty • High Accuracy positive result • Easy to use • Low awareness on H.pylori • bacteria High market potential • Currently Immature market • Lack of direct competition in regards to self diagnosis • Possible conflict with Private Laboratories
  • 7. H. Pylori - Target Audience  Public 30+ years old, all socio-economic classes, throughout Greece.  Selling/Purchasing Points  Pharmacies  Doctors  Pathologists, General Practitioners, Gastroenterologists
  • 8. Strategic Plan Objectives Strategies Tactics Design leaflets -Stomach Ulcer information leaflets for public  Grow the market Create Awareness - Product leaflets for selling points and HP  Establish the Promote product’s accuracy Sales & Promotional data and unique technical product Activities specifications in HPs Product’s introduction & detailing in Pharmacies and  Gain Medical Activate Consumer targeted doctors Community’s dynamics Media-advertising campaign referrals Publicity in Professional magazines Exhibit in Medical Congress
  • 9. Prostate Cancer Infection rate: It is the most frequent malignancy for men above 45 years old. In Europe 7% of the total male population will develop the disease. Potential Market in Greece: 2.500.000 in Total Male Population Current Diagnostic pathway: o Clinical examination & DRE o PSA (Cost per examination 80€-102€ in Private labs) o Regular level below 4 ng/mL o Suspicious level 4-10 ng/mL o Dangerous level above 10 ng/mL o Sonografy o Biopsy
  • 10. The Self-Diagnostic device • PSA self-test – the new self-testing solution – Simple, quick and reliable – Qualitative results – 1st step for PSA identification
  • 11. PSA self-test Positives Negatives • First self-testing product in • Immature market in regards to the Greek market self diagnosis • Not a complete examination with • High Accuracy specific quantitative results • Easy to use • A further PSA lab examination is • Time saving required in case of a positive result • Lack of direct competition • Its reliability might be questioned
  • 12. PSA - Target Audience  Male Public 45+ years old, all socio-economic classes, throughout Greece.  Selling/Purchasing Points  Pharmacies  Doctors  Urologists, General Practitioners.
  • 13. Strategic Plan Objectives Strategies Tactics Design leaflets  Penetrate the Sales & Promotional - Product leaflets for selling market Activities points and HPs Promote product’s value & convenience  Establish the self Activate Consumer Product’s introduction & diagnostic solution dynamics detailing in Pharmacies and targeted doctors  Gain Medical Publicity in Professional magazines Community’s Dynamic Media campaign referrals Exhibit in the National Urological congres
  • 14. Healthcare products Rolling forecast in # of eaches Month Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec YE Year Type Fcast Fcast Fcast Fcast Fcast Fcast Fcast Fcast Fcast Fcast Fcast Fcast Total Fcast PSA 1000 1.000 1.500 2.000 3.000 3.000 2.000 1.000 2.500 3.500 3.500 2.500 26.500 2011 H.pylori 500 750 1.000 1.000 500 1.000 1.500 2.000 1.500 9.750 PSA 3.000 3.500 4.000 4.000 5.000 5.000 3.000 2.000 3.000 4.500 5.000 4.000 46.000 2012 H.pylori 2.000 2.000 3.000 3.000 3.500 3.500 3.000 2.000 3.000 3.500 4.000 3.000 35.500 Depending on our Strategic Planning impact, forecast can be revised upwards within Q2 2010